Philip Andrew Gioia has been appointed president North America and Global API business at Glenmark Pharmaceuticals. Mr. Gioia will be responsible for the generics and branded business across North America and also Global API sales and marketing. Mr. Gioia will be based in Mahwah, NJ and will report to Glenn Saldanha, chairman and managing director. He brings more than 25 years of experience in the U.S. pharmaceutical industry.
 
Mr. Gioia joins the company from Bausch & Lomb (acquired by Valeant Pharmaceuticals), where he most recently served as global head of diversified products and business development, Pharmaceuticals. Prior to that, he was division head of the Pharmaceutical Business Unit, North America, responsible for all aspects of P&L management, in addition to overall strategic commercial operations for the brand, generic and OTC divisions.
 
Prior to Bausch & Lomb, he spent 13 years at Barr Pharmaceuticals in roles of increased responsibility, including vice president and senior vice president of sales, and senior vice president of the $1.6 billion U.S. Generic Sales & Marketing business. He also led the forecasting group and was involved in product selection, planning, and logistics.